Sumitomo Mitsui Trust Group
PACB icon

Sumitomo Mitsui Trust Group’s Pacific Biosciences PACB Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Sell
6,009,715
-1,028,272
-15% -$1.5M 0.01% 673
2026
Q1 		$9.29M Sell
7,037,987
-770,593
-10% -$1.38M 0.01% 676
2025
Q4 		$14.6M Sell
7,808,580
-868,978
-10% -$1.67M 0.01% 653
2025
Q3 		$11.1M Sell
8,677,558
-540,897
-6% -$732K 0.01% 676
2025
Q2 		$11.4M Sell
9,218,455
-346,876
-4% -$401K 0.01% 664
2025
Q1 		$11.3M Sell
9,565,331
-613,170
-6% -$941K 0.01% 682
2024
Q4 		$18.6M Sell
10,178,501
-1,687,265
-14% -$3.29M 0.01% 654
2024
Q3 		$20.2M Sell
11,865,766
-774,795
-6% -$1.27M 0.01% 635
2024
Q2 		$17.3M Sell
12,640,561
-183,824
-1% -$371K 0.01% 658
2024
Q1 		$48.1M Sell
12,824,385
-375,990
-3% -$2.2M 0.03% 505
2023
Q4 		$129M Sell
13,200,375
-247,291
-2% -$2.02M 0.1% 218
2023
Q3 		$112M Sell
13,447,666
-202,282
-1% -$2.31M 0.09% 226
2023
Q2 		$182M Sell
13,649,948
-356,567
-3% -$4.33M 0.14% 152
2023
Q1 		$162M Sell
14,006,515
-159,678
-1% -$1.59M 0.12% 178
2022
Q4 		$116M Sell
14,166,193
-225,769
-2% -$1.95M 0.09% 252
2022
Q3 		$83.5M Buy
14,391,962
+46,477
+0.3% +$267K 0.07% 332
2022
Q2 		$63.4M Buy
14,345,485
+324,280
+2% +$1.97M 0.05% 421
2022
Q1 		$128M Buy
14,021,205
+2,106,180
+18% +$24.2M 0.09% 260
2021
Q4 		$244M Buy
11,915,025
+2,567,023
+27% +$61.9M 0.15% 149
2021
Q3 		$239M Buy
9,348,002
+1,215,677
+15% +$36M 0.15% 143
2021
Q2 		$284M Buy
8,132,325
+2,929,012
+56% +$85.2M 0.17% 136
2021
Q1 		$173M Buy
5,203,313
+725,219
+16% +$25.4M 0.11% 207
2020
Q4 		$116M Buy
4,478,094
+361,541
+9% +$6.14M 0.08% 299
2020
Q3 		$40.6M Buy
+4,116,553
New +$23.7M 0.03% 548

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group's PACB Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group reduced its Pacific Biosciences (PACB) stake by 15% in Q2 2026, selling an estimated $1.5M and leaving 6,009,715 shares worth $10.1M. The position accounts for 0.01% of the portfolio, ranked #673.

Sumitomo Mitsui Trust Group first reported a position in PACB in Q3 2020 and has held it in 24 quarters since. The position peaked at $284M in Q2 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Sumitomo Mitsui Trust Group held 6,009,715 shares of Pacific Biosciences worth $10.1M as of Q2 2026.
  • Sumitomo Mitsui Trust Group sold 1,028,272 Pacific Biosciences shares in Q2 2026, an estimated $1.5M.
  • Pacific Biosciences made up 0.01% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #673 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Pacific Biosciences in Q3 2020 and has held it in 24 quarters since.
  • Sumitomo Mitsui Trust Group's Pacific Biosciences position peaked at $284M in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.